February 12, 2025
FDA to review Regeneron’s linvoseltamab BLA for multiple myeloma treatment
The US Food and Drug Administration (FDA) has accepted to review Regeneron Pharmaceuticals’ resubmitted biologics license application (BLA) for linvoseltamab to treat adults with relapsed/refractory (R/R) multiple myeloma (MM).